APIXABAN App Study
Recruiting · NCT06903845 · Interventional (participants receive a specific treatment) · Lead sponsor:
Dong-Ju Choi
View the official record on ClinicalTrials.gov →
Interventions studied
Medication reminder appvideo call
What this trial is about
The aim of this clinical trial is to evaluate whether the medication reminder app and video call can improve medication adherence to apixaban in patients with AF and comorbidities.
Patients with AF and comorbid heart disease taking apixaban who meet the inclusion criteria will be randomised 1:1 to a treatment arm using a medication reminder app and bi-weekly video education and a control arm using the medication reminder app alone to compare medication adherence.
Patients in both groups will use the medication app, but only the treatment group will receive additional education and feedback via video call every two weeks to reinforce the use of the medication app and medication reminders with video education.
The study aims to assess the change in adherence between the two groups at week 8.
Who can take part
Age range
19 Years and older
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Eligibility criteria (as published)
Participants must meet all of the following criteria:
Adults aged 19 years or older with a diagnosis of atrial fibrillation (AF)
Presence of at least one of the following cardiovascular or metabolic comorbidities:
A. Heart failure
B. Hypertension
C. Coronary artery disease
D. Peripheral arterial disease
E. Diabetes mellitus
F. Stroke
G. Other cardiac diseases requiring treatment
Currently taking or planning to initiate oral anticoagulation therapy with apixaban
Able to use a smartphone with an Android operating system
Voluntarily provided written informed consent to participate in the clinical trial after being adequately informed of its purpose, procedures, and potential risks
2\. Exclusion Criteria
Participants will be excluded if any of the following conditions apply:
Creatinine clearance (CCr) \< 15 mL/min
Presence of moderate to severe mitral stenosis
History of mitral valve repair or replacement
Clinically significant history of alcohol or substance abuse
Deemed by the investigator to be legally or psychologically unsuitable for participation in the clinical trial
Participation in another clinical trial involving investigational drugs within 4 weeks prior to screening
Declines or is unwilling to provide informed consent for participation in this study
Where it is running
1 location listed.
Read the full protocol, contacts and eligibility on ClinicalTrials.gov →